SCHEMBL30135008

SCHEMBL30135008

Cc1cc(NC(=O)[C@@H](CC(C)C)NC(=O)OC(C)(C)C)cc(C)c1-c1ccnc2c1ccn2S(=O)(=O)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.41
REN P00797 2/20 0.39
AAK1 Q2M2I8 1/20 0.39
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
POLB P06746 1/20 0.38
PIK3C3 Q8NEB9 2/20 0.38
HTT P42858 2/20 0.38
MAP1LC3B Q9GZQ8 1/20 0.38
MAP1LC3A Q9H492 1/20 0.38
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
PLA2G1B P04054 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
XBP1 P17861 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
ATG4B Q9Y4P1 1/20 0.37
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30135091 0.93 EGFR (0.44) EGFRRENAAK1KMT2AMEN1
SCHEMBL30135026 0.91 CIT (0.42) EGFRRENAAK1KMT2AMEN1
SCHEMBL30134921 0.89 EGFR (0.48) EGFRRENAAK1KMT2AMEN1
SCHEMBL30134898 0.89 EGFR (0.46) EGFRRENAAK1KMT2AMEN1
SCHEMBL30134934 0.89 CIT (0.43) EGFRRENAAK1KMT2AMEN1
SCHEMBL30135242 0.89 CIT (0.43) EGFRRENAAK1KMT2AMEN1
SCHEMBL30134973 0.88 EGFR (0.43) EGFRRENAAK1KMT2AMEN1
SCHEMBL30135063 0.87 PIK3C3 (0.43) EGFRRENAAK1KMT2AMEN1
SCHEMBL30134929 0.87 CIT (0.42) EGFRRENAAK1KMT2AMEN1
SCHEMBL30134907 0.87 EGFR (0.43) EGFRRENAAK1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243196-A1 CITRON KINASE INHIBITORS THE CLEVELAND CLINIC FOUNDATION 2025-07-31 US disclosed
WO-2022216717-A1 CITRON KINASE INHIBITORS THE CLEVELAND CLINIC FOUNDATION (US) 2022-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250243196-A1 CITRON KINASE INHIBITORS CHEK2, CILK1, DCK EGFR 645/4885REN 4031/4885AAK1 436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.